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INTRODUCTION
Bronchial asthma is defined as a chronic inflammatory dis-
order of the airway (1). Previous studies have demonstrated
the airway inflammation in bronchial asthma directly by bron-
choscopic biopsies (2), bronchoalveolar lavages (3), or sputum
examinations (4), and indirectly by measurements in periph-
eral blood (5). The examination of sputum induced by inhala-
tion of hypertonic saline has introduced, and it is known to be
a valuable and reproducible method to evaluate eosinophilic
asthmatic inflammation. The increase in blood eosinophils and
serum eosinophil cationic protein (ECP) may be a useful, indi-
rect marker of airway inflammation in asthma (6). Pizzichini
et al. (7) reported that proportion of eosinophils in sputum is
a more accurate marker of asthmatic airway inflammation
than the proportions of blood eosinophils or serum ECP.
Nitric oxides (NO) may amplify and perpetuate allergic
inflammation by selective inhibition of helper T lymphocytes
(Th1) which secrete interferon (IFN)- , and in turn suppress
the proliferation of Th2 lymphocytes (8). Nitric oxide (NO)
concentration in exhaled air and sputum is increased in patients
with asthma (8-10). We reported that NO metabolites in in-
duced sputum are more valuable indicators to monitor asth-
matic airway inflammation than those in serum are (11).
To measure the diagnostic accuracy of serum and sputum
markers of airway inflammation, this study was designed to
compare NO metabolites, eosinophils, and ECP of sputum
with those of serum obtained in asthmatic patients and con-
trol subjects.
MATERIAL AND METHODS
Subjects
Fifteen patients with asthma and ten control subjects were
recruited for this study. Control subjects, who volunteered for
this study, had no history of any respiratory symptoms, and
had forced expiratory volume in one second (FEV1) >75%
predicted, a ratio of FEV1 to forced vital capacity >75%, and
a normal methacholine airway responsiveness [provocation
concentration of methacholine producing a 20% fall of FEV1
(PC20) >16 mg]. The diagnoses of asthma were established in
the patients by their symptoms of recurrent episodic wheez-
ing, coughing, and/or dyspnea, accompanied either by metha-
choline airway hyperresponsiveness (nine patients) or by a sig-
nificant improvement of FEV1 (15%) following anti-asthma
therapy (six patients). No subject had respiratory infections for
4 weeks prior to the study. Cheju National University Hos-
pital Research Committee approved the study and all subjects
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Nitric Oxide Metabolites, Eosinophils, and Eosinophilic Cationic 
Protein in Patients with Asthma: Sputum versus Blood
The monitoring of airway inflammation has assessed in bronchial asthma directly by
sputum examination, and indirectly by measurements in peripheral blood. To inves-
tigate the diagnostic value of these two methods, we compared nitric oxide (NO) me-
tabolites, eosinophils, and eosinophil cationic protein (ECP) in sputum and blood in
patients with asthma and control subjects. Sputum and serum were obtained from
fifteen patients with asthma, and then were examined before anti-asthma treatment,
including steroid preparations. ECP was measured by fluoroimmunoassay. NO me-
tabolites were assayed by using modified Griess reaction. Asthmatic patients, com-
pared with control subjects, had significantly higher level of NO metabolites, higher
proportion of eosinophils, and higher levels of ECP in sputum. Asthmatic patients,
compared with control subjects, however, had significantly higher number of eosi-
nophils, and were at higher levels of ECP in blood. FEV1, FEV1/FVC was negatively
correlated with sputum eosinophils. The area under receiver operating characteristic
(ROC) curve showed that eosinophils in sputum are significantly accurate markers
than NO metabolites in sputum and blood. These findings suggest that the propor-
tion of eosinophils in sputum have more accurate diagnostic marker of asthmatic air-
way inflammation than NO metabolites in sputum in differentiating asthmatic patients
from control subjects.
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gave written and informed consents prior to participation.
Study design
Eosinophils and inflammatory markers in sputum and serum
were measured in asthmatic patients, and were compared to
those in control subjects. On visit, a questionnaire for symp-
toms and medications was given, and a spirometry was per-
formed. Then, sputum and serum were collected, and skin
prick tests and methacholine provocation test were done. Clin-
ical severity of asthma was classified by the method of Interna-
tional Consensus Report (12). A person new to the clinical
characteristics of subjects examined all measurements in spu-
tum and serum.
Spirometry was performed according to American Thoracic
Society standards (13) using SensorMedics 2200 spirometer
(Cardiopulmonary Care CompanyTM, Yorba Linda, CA, U.S.A.).
The representative values for FVC and FEV1 were selected
according to International Thoracic Society criteria (14), and
the reference values were taken from the reports by Choi et al.
(15) and by Kim et al. (16). Methacholine challenge tests were
carried out by the modification of method described by Chai
et al. (17) and the results were expressed as PC20 in noncumu-
lative units. Allergy skin prick tests were performed using 55
commercially available inhalant allergens. Atopy means one
or more positive allergy skin prick tests.
Sputum Sampling and Processing
Sputum was induced only when it could not be produced
spontaneously. Sputum induction was performed as described
by Fahy et al. (18). All subjects were premedicated with inhaled
salbutamol 2 puffs (200  g). Subjects inhaled 3% hyperton-
ic saline solution aerosols generated by an ultrasonic nebuliz-
er (NE-U03, OMRON Co., Tokyo, Japan) with maximum
output of 0.15-0.3 mL/min and mass median aerodynamic
diameter of 4.5  m. Hypertonic saline was inhaled for 25-30
min according to the severity of asthma, until adequate volume
of sputum expectorated. Subjects were asked to rinse their
mouth, and blow the nose to minimize contamination with
saliva and postnasal drip. They were encouraged to cough
deeply and frequently during hypertonic saline inhalation.
They were instructed to cough the sputum into a sterile plas-
tic container. The volumes of samples and the duration of
sputum induction were recorded. FEV1 was measured before,
during, and after induction of sputum. Sputum induction was
stopped in subject with a fall of the FEV1 greater than 15%.
Sputum was selected from saliva and processed within 2 hr.
The method of sputum examination described by Popov et al.
(19) was modified (18). Sputum was treated by adding equal
volumes of 0.1% dithiothreitol (Sputalysin 10%; Gibco BRL,
U.S.A.) followed by equal volumes of Dulbecco’ s phosphate
buffered saline (D-PBS). The sample was then mixed gently
and placed in a shaking water bath at 37℃for 15 min to en-
sure complete homogenization. The sample was removed from
the water bath periodically for further brief and gentle mix-
ing. The suspension was filtered through gauze (1 mm pore
size). The filtrate was centrifuged at 1,500 rpm for 10 min,
and the supernatant was aspirated and stored in Eppendorf
tubes at -70℃for later assay. The cell pellet was resuspended
in D-PBS 1,000  L, and the total number of nonsquamous
cells were counted in a modified Neubauer hemocytometer.
The cell suspension was adjusted to 0.5×105/mL, and then
50  L of cell suspension was placed into cups of Sakura cyto-
centrifuge (Model CF-127, Tokyo, Japan). Two coded cytospins
were prepared at 600 rpm at 5 min, air dried, and then stained
by Diff-Quick (Kookje Scientific Products, Japan) stain. Cell
differentials of 400 nonsquamous cells were performed in Diff-
Quick stained slides by two investigators who did not know the
history of the subject, and the results were expressed as a per-
centage of the total nonsquamous cell count.
Blood Sampling
Venous blood (5.0 mL) was collected into a tube containing
ethylenediaminetetraacetic acid (K3 Vacutainer BD, Ruther-
fold, NJ, U.S.A.) before the sputum induction and differential
white blood cell count was performed by review of Wright
staining of venous blood. Serum was collected after blood
coagulation for 30 min at room temperature. It was cen-
trifuged at 1,500 rpm for 10 min, and then stored in Eppen-
dorf tubes at -70℃for later assay.
ECP Measurement
The concentration of ECP in 400  L in thawed supernatant
and serum was determined using fluoroimmunoassay (Uni-
CAP system, Sweden). Samples were analyzed in duplicates.
The limit of detection for ECP assays was 2.0  g/L.
Nitrite and Nitrate assay
Nitrite production was colorimetrically quantified after the
Griess reaction, as described by Greenberg et al. (20). One
hundred  L of sputum supernatant and serum or standard
reacted with equal volume of Griess reagent (1% sulfanilamide/
0.1% naphthylethyllene dihydrochloride/2.5% phosphoric
acid, Sigma Chemical Co.) in duplicate microtiter wells at
room temperature. Chromophore absorbance at 540 nm was
determined. Nitrite concentration was calculated using sodi-
um nitrite (BDH Chemical Co., U.S.A.) as a standard.
For assay of nitrate of samples, 200  L sputum supernatant
and serum or standard containing 100  L of 200mM ammo-
nium formate (including 100 mM HEPES, Sigma Chemical
Co.) was reduced to nitrite at 37℃for 1 hr by adding 100 L
nitrate reductase [E. coli (ATCC25922), American Type Col-
lection, Rockville, MD, U.S.A.], followed by centrifugation to
precipitate nonreacting E. coli for 5 min, and then the nitritewas quantified as described above.
Statistical Analysis
All data were analyzed using the SPSS version 7.5 for Win-
dows. Data are expressed as mean±SEM. Comparison of vari-
ables was performed using Student’ s t test, Mann-Whitney U
test. Pearson’ s correlations and Spearman’ s correlations were
used to assess relationships between variables. Because the vari-
ables had a continuous scale of values, where the selection of
a cutoff point was arbitrary, we determined the diagnostic accu-
racy of sputum and serum NO metabolites by generating a
receiver operating characteristic (ROC) curve (21). The area
under the curves (AUCs) was compared by the method of Han-
ley and McNeil (22). A p-value <0.05 was considered signif-
icant.
RESULTS
Characteristics of the subject are given in Table 1. Asthmat-
ic patients had significantly lower FEV1, FEV1/FVC than con-
trol subjects (p<0.01).
NO Metabolites, Eosinophils, and Eosinophil Cationic
Protein between Asthmatic Patients and Control sub-
jects
Asthmatic patients, compared with control subjects, had
significantly higher proportion of higher NO metabolites
(1220.3±180.2  mol/L vs. 545.6±98.4 mol/L,  p<0.01),
eosinophils (49.5±5.3% vs. 2.7±0.5%, p<0.01), and high-
er levels of ECP (1345.1±201.5  g/L vs. 146.5±27.5 g/L,
p<0.01) in sputum. Asthmatic patients, compared with con-
trol subjects, however, had significantly higher numbers of
eosinophils (1069.0±440.6/ L vs. 124.4±31.9/ L, p<0.01),
and higher levels of ECP (39.1±8.5  g/L vs. 3.5±1.7 g/L,
p<0.01) in blood.
Correlations between Inflammatory Markers and Clin-
ical Findings
FEV1, FEV1/FVC was negatively correlated with sputum
eosinophils (r=-0.56, p<0.05; r=-0.69, p<0.01, Table 2). FEV1
was negatively correlated with the levels of ECP in sputum
(r=-0.58, p<0.05). Significant positive correlations were noted
between sputum eosinophils and sputum-ECP, sputum NO
(r=0.59, r=0.547; respectively p<0.05). Significant positive
correlations were noted between serum eosinophils and serum-
ECP (r=0.58, p<0.05).
Comparing AUCs
The area under ROC curve showed that eosinophils in spu-
tum (0.94) are significantly accurate markers than NO metabo-
lites in sputum (0.79) and serum (0.52) (p<0.05, respective-
ly, Fig. 1). Although the area under ROC curve showed that
eosinophils in sputum (0.95) are greater than that of ECP in
sputum, eosinophils, and ECP in serum (0.838, 0.842), there
were no significant differences.
DICSUSSION
In this study, we compared the NO metabolites, eosinophils,
ECP in sputum, and peripheral blood to biochemical markers
of airway inflammation in the control and asthmatic subjects.
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Data expressed as mean±SEM. *p<0.01.
Control subjects Asthmatics
Subjects (No.) 10 15
Age (yr) 33±7.1 38.2±2.5
Sex (M/F) 8/2 9/6
Atopic (No.) 3 8
PC20 (mg/mL) >16 1.78±0.53
FEV1 (%pred)* 92.6±1.0 69.3±3.5
FVC (%pred) 86.5±3.9 74.2±2.9
FEV1/FVC (%)* 90.4±2.1 68.5±3.2
Table 1. Characteristics of subjects 
Correlations only with values of rs >0.50 and p<0.05 are given.
SpEo, sputum eosinophils; SpECP, sputum ECP; SpNO, sputum NO
metabolites; BEo, blood eosinophils; SECP, serum ECP; SNO, serum
NO metabolites; NS, not significant.
SpEo SpECP SpNO BEo SECP SNO
FEV1 (%pred) -0.56 -0.58 NS NS NS NS
FEV1/FVC -0.69 NS 0.53 NS NS NS
SpECP 0.58 - 0.547 NS NS NS
SECP NS NS NS 0.58 - NS
SpNO 0.59 0.55 - NS NS NS
Table 2. Correlations between inflammatory markers and clinical
findings
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Fig. 1. Comparison AUCs in sputum and blood. Plots lie farthest
to the ‘northwest’ represent more accurate values.492 A.-S. Jang, C.-H. Yeum, I.-S. Choi
Our principal findings are that the proportion of eosinophil,
ECP, and NO metabolites in sputum is higher in asthmatic
patients than in control subjects, and that the proportion of
eosinophil and the level of ECP is higher in serum in asthmat-
ic patients than in control subjects. Together, these findings
suggest that the proportion of eosinophil, ECP in sputum, and
serum is a more accurate marker of asthmatic airway inflam-
mation than NO metabolites in sputum and serum.
Until recently, direct measurement of indices of airway in-
flammation was possible by bronchoscopic biopsy (2), or BAL
(3). The examination of sputum selected from saliva, the use
of dithiothreitol to disperse the mucus, and the use of cytospins
provide a direct research tool to measure activation markers,
inflammatory mediators, and cellular functions pertinent to
asthma pathogenesis noninvasively (23, 24).
It has been suggested that the increase in blood eosinophil
and serum ECP may be useful and indirect markers of airway
inflammation in asthma (6). Pizzichini et al. (7) suggested that
the proportion of eosinophils in sputum is a more accurate
marker of asthmatic airway inflammation than the proportion
of blood eosinophils or serum ECP. Our study is the first com-
parison of diagnostic accuracy between NO metabolites, eosi-
nophil, and ECP in sputum and peripheral blood samples.
NO may amplify allergic inflammation by selective inhi-
bition of T lymphocytes that secrete IFN- (Th1), which sup-
presses the proliferation of Th2 cells (8). NO is endogenous-
ly derived from the amino acid L-arginine by three forms of
the NO synthases (NOS). Two constitutive NOS are involved
in physiological regulation of airway function, and inducible
NOS is involved in inflammatory disease of the airways (8).
Several authors reported that NO in exhaled air increased in
asthmatic subjects (25-27). Measurement of exhaled NO con-
centration may be clinically useful in detection and manage-
ment of cytokine mediated inflammatory lung disorders (28).
Kanazawa et al. (7) reported that measurement of NO deriva-
tives in induced sputum may be useful for assessing allergic
inflammation in airways. We reported that the level of NO
metabolites were increased in the tracheo-bronchial secretion
of asthmatic subjects, and was paralleled with severity of asth-
ma (29). Measurement of NO metabolites in induced sputum
may be used for monitoring the degree of airway inflamma-
tion in asthmatics. The authors reported that the AUC for each
test revealed that level of NO metabolites in induced sputum
was more sensitive and specific than the determinations of se-
rum NO metabolites in differentiating of patients with asth-
ma from control subjects. These finding imply that NO con-
tributes to inflammation limited to tracheo-bronchial tree. In
this study, we observed the different properties of sputum and
peripheral blood sample examinations. The examination of
eosinophils, ECP, NO metabolites in asthma is relevant be-
cause they are considered to be involved in asthmatic airway
inflammation, and this inflammation causes recurrent episodes
of wheezing, breathlessness, chest tightness, coughing, and
variable airflow obstruction. In the present study, eosinophils
and the level of ECP in sputum were negatively correlated
with severity of airway obstruction (FEV1, FEV1/FVC).
When we compared NO metabolites, eosinophils, and ECP
in sputum and serum in patients with asthma and control
subjects, the area under ROC curve showed that the propor-
tion of eosinophils in sputum is a significantly accurate mark-
er than NO metabolites in sputum and serum. Although the
area under ROC curve showed that eosinophils in sputum are
greater than that of ECP in sputum, eosinophils, and ECP in
serum, there were no significant differences.
In conclusion, these findings suggest that the proportion
of eosinophils in sputum have more accurate diagnostic mark-
er of airway inflammation than NO metabolites in sputum
and serum in differentiating asthmatic patients from control
subjects.
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